Evidence mapPaperPMID 32654397Full record

ReviewThe FEBS journal2021

Targeting hepatocyte carbohydrate transport to mimic fasting and calorie restriction.

Jacqueline Kading, Brian N Finck, Brian J DeBosch

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in The FEBS journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Hepatic Suppression of Mitochondrial Complex II Assembly Drives Systemic Metabolic Benefits.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jacqueline KadingDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
Brian N FinckDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Brian J DeBoschDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-9924-7921
Washington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
Washington University Nutrition Obesity Research CenterP30DK056341 · WASHINGTON UNIVERSITY · 1999 to 2025
$5.7M
Targeting the mitochondrial pyruvate carrier to treat insulin resistance and nonalcoholic fatty liver diseaseR01DK104735 · NIDDK · WASHINGTON UNIVERSITY · 2022 to 2025
$4.2M
NCATS NIH HHS UL1 TR002345NCCIH NIH HHS R21 AT010520NHLBI NIH HHS R01 HL147968NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK104735NIDDK NIH HHS R01 DK117657NIDDK NIH HHS R01 DK126622NIDDK NIH HHS R56 DK115764
6 · The paper itself

Abstract

The pervasion of three daily meals and snacks is a relatively new introduction to our shared experience and is coincident with an epidemic rise in obesity and cardiometabolic disorders of overnutrition. The past two decades have yielded convincing evidence regarding the adaptive, protective effects of calorie restriction (CR) and intermittent fasting (IF) against cardiometabolic, neurodegenerative, proteostatic, and inflammatory diseases. Yet, durable adherence to intensive lifestyle changes is rarely attainable. New evidence now demonstrates that restricting carbohydrate entry into the hepatocyte by itself mimics several key signaling responses and physiological outcomes of IF and CR. This discovery raises the intriguing proposition that targeting hepatocyte carbohydrate transport to mimic fasting and caloric restriction can abate cardiometabolic and perhaps other fasting-treatable diseases. Here, we review the metabolic and signaling fates of a hepatocyte carbohydrate, identify evidence to target the key mediators within these pathways, and provide rationale and data to highlight carbohydrate transport as a broad, proximal intervention to block the deleterious sequelae of hepatic glucose and fructose metabolism.

Indexed as

AnimalsBiological TransportCaloric RestrictionCarbohydrate MetabolismDisease Models, AnimalFastingGene ExpressionGlucoseGlucose Transport Proteins, FacilitativeHepatocytesHumansLiverMembrane Transport ModulatorsMetabolic SyndromeMolecular Targeted TherapyObesityGlucoseGlucose Transport Proteins, FacilitativeMembrane Transport Modulatorscaloric restrictionChREBPfibroblast growth factor 21fructoseglucokinaseGLUTintermittent fastingketogenic dietmitochondrial pyruvate carriertrehalose

Identifiers

PMID32654397
PMCPMC8662989
OpenAlexW3040864622

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.